Treatment of postoperative wounds (particularly refractory wounds) in the anus using a basic fibroblast growth factor

Trafermin (fibroblast spray) is the world's first topical cytokine therapeutic drug containing human ba-sic fibroblast growth factor (bFGF) as the main ingredient. bFGF is produced with a human recombinant DNA technology. This drug specifically binds to the FGF receptors existing on the vascular endothelial cells and the cell membrane of the fibroblast and directly stimulates angiogenesis, accelerated granulation, and accelerated cutization. In the present study, when Trafermin was administered to 12 patients showing prolonged postoperative healing of anal fistula (2 months to 1 year and 3 months after operation), 11 patients showed complete healing within 2 weeks. In the treatment of 10 patients with transsphincteric fistula and suprasphincteric fistula by a seton method, it was possible to shorten dramatically the healing time using this drug as concomitant therapy. Trafermin is expected to change greatly the treatment of anal diseases in the near future.